摘要
目的对非痰标本来源的肠杆菌科细菌抗菌素耐药趋势进行调查分析,为临床合理使用抗菌药物提供参考依据。方法收集华西医院2007-2011年,住院患者送检非痰标本中分离到的肠杆菌科细菌临床数据,采用WHONET 5.5和SPSS16软件进行统计分析。结果 5年从非痰标本中分离肠杆菌科细菌8322株。非痰液标本构成以尿液(32%)、分泌物(26%)及血液(16%)为主,菌株构成以埃希菌属(55%)、克雷伯菌属(17%)及肠杆菌属(14%)为主。肠杆菌科细菌对氨苄西林、头孢唑林的耐药率较高,对哌拉西林/三唑巴坦、亚胺培南耐药率较低。对亚胺培南敏感的细菌,其MIC值有左移趋势,哌拉西林/三唑巴坦和亚胺培南交叉耐药率低(0.3%)。肠杆菌各菌属对部分抗菌药物耐药率有逐年下降的趋势。结论宣传合理用药,加强检验质量,控制院内感染是降低细菌耐药性的重要手段。
Objective To improve in clinical treatment, the antibiotic resistance of Enterobacteriaceae isolated from non-sputum specimens in the West China Hospital from 2007 to 2011 were investigated. Methods The susceptibility to regular antibiotics of Enterobacteriaceae was investigated and its variance was analyzed for antibiotic management policy evaluation. WHONET 5.5 and SPSS 16 softwares were adopted to calculate the analytical resistance rate. Results For the 5 years surveillance, 8322 strains of Enterobacteriaceae strains were isolated from non-sputum specimens. The distribution of clinical samples for Enterobacteriaceae mainly comes from urine （32%）, secretion （26%） and blood （16%）. Composition of microorganisms were Escherichia （55%）, Klebsiella （17%） and Enterobacter （14%）. For ampicillin and cefazolin, Enterobacteriaceae bacteria was showed more serious resistance. However, the resistance to piperacillin/tazobactam and imipenem were low. In five consecutive years of investigation, the susceptibility of imipenem in Enterobacteriaceae was showed the tendency to sensitive. The cross resistance of piperacillin/tazobactam and imipenem is extremely low, only 0.3%. Most Enterobacteriaceae were statistically showed more sensitive to regular antibiotics （P〈0.05）. Conclusion Improvement of clinical treatment, antibiotic management and hospital acquired infection policy was an important approach to reduce bacterial resistance.
出处
《中国抗生素杂志》
CAS
CSCD
北大核心
2014年第5期357-360,374,共5页
Chinese Journal of Antibiotics
基金
国家自然科学基金(No.81000712)
关键词
肠杆菌科
抗生素
耐药率
Enterobacteriaceae
Antibiotics
Resistance
